Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 comparison of JNJ-79635322 versus an anti-BCMAxCD3 bispecific antibody in relapsed or refractory multiple myeloma
NL-OMON61132Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ramantamig in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started May 2026; status: recruiting.
02
Drugs
ramantamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON61132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61132.